Positions

Overview

  • Dr. Sudarshan received his undergraduate degree from Duke University, followed by his medical school training at the Duke University School of Medicine. He subsequently completed his residency in Urologic surgery at the Medical University of South Carolina. It was during his residency that he investigated gene therapy-based strategies for genitourinary malignancies. Dr. Sudarshan further pursued his interest in urologic oncology by completing a fellowship at the National Cancer Institute of the National Institutes of Health. During this fellowship, Dr. Sudarshan's clinical interests encompassed the utilization of minimally invasive approaches to the management of urologic cancers, including advanced laparoscopic techniques for renal/adrenal malignancy as well as robotic-assisted laparoscopic prostatectomy.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Integrative epigenetic and gene expression analysis of renal tumor progression to metastasisCell Growth and Differentiation.  17:84-96. 2019
    2018 Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancerClinical Cancer Research.  24:6433-6446. 2018
    2018 Wnt receptor Frizzled 8 is a target of ERG in prostate cancerProstate.  78:1311-1320. 2018
    2017 Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinomaOncotarget.  8:29220-29232. 2017
    2016 Kinase gene expression profiling of metastatic clear cell renal cell carcinoma tissue identifies potential new therapeutic targetsPLoS ONE.  11. 2016
    2016 Genetics of renal cancer: focus on MTORAging.  8:421-422. 2016
    2015 High throughput kinomic profiling of human clear cell renal cell carcinoma identifies kinase activity dependent molecular subtypesPLoS ONE.  10. 2015
    2015 Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancerOncoscience.  2:483-486. 2015
    2015 Point mutations of the mTOR-RHEB pathway in renal cell carcinomaOncotarget.  6:17895-17910. 2015
    2014 Do the sites of metastases provide additional information regarding prognosis and biology in renal cell carcinoma?European Urology.  65:585-586. 2014
    2014 Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinomaExpert Opinion on Investigational Drugs.  23:305-315. 2014
    2014 L-2-hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancerCancer Discovery.  4:1290-1298. 2014
    2014 The oncometabolite fumarate promotes pseudohypoxia through noncanonical activation of NF-κB signalingJournal of Biological Chemistry.  289:24691-24699. 2014
    2013 The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-dependent signalingMolecular Cell.  51:236-248. 2013
    2013 The Proto-oncometabolite Fumarate Binds Glutathione to amplify ROS-dependent signalingMolecular Cell.  51:273. 2013
    2013 Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translationOncogene.  32:3147-3155. 2013
    2013 PI3K regulation of the SKP-2/p27 axis through mTORC2Oncogene.  2027-2036. 2013
    2013 Metabolism of kidney cancer: From the lab to clinical practiceEuropean Urology.  63:244-251. 2013
    2012 Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- productionPLoS ONE.  7. 2012
    2011 Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasionPLoS ONE.  6. 2011
    2010 Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinomaCell Cycle.  9:4183-4189. 2010
    2010 Repeat Partial Nephrectomy on the Solitary Kidney: Surgical, Functional and Oncological OutcomesJournal of Urology, The.  183:1719-1724. 2010
    2009 Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1α stabilization by glucose-dependent generation of reactive oxygen speciesMolecular and Cellular Biology.  29:4080-4090. 2009
    2009 Renal Cell Carcinoma: Recent Advances in Genetics and ImagingSeminars in Ultrasound, CT and MRI.  30:315-325. 2009
    2008 Feasibility and Outcomes of Repeat Partial NephrectomyJournal of Urology, The.  180:89-93. 2008
    2008 Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and OutcomesJournal of Urology, The.  179:67-70. 2008
    2007 Pseudohypoxic pathways in renal cell carcinomaClinical Cancer Research.  13:4667-4671. 2007
    2007 HIF and fumarate hydratase in renal cancerBritish Journal of Cancer.  96:403-407. 2007
    2007 Mechanisms of disease: Hereditary leiomyomatosis and renal cell cancer - A distinct form of hereditary kidney cancerNature Clinical Practice Urology.  4:104-110. 2007
    2006 Genetic Basis of Cancer of the KidneySeminars in Oncology.  33:544-551. 2006
    2005 Abnormal fluorescence in situ hybridization analysis in collecting duct carcinomaUrology.  66:1110.e9-1110.e11. 2005
    2005 In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancerCancer Gene Therapy.  12:12-18. 2005
    2003 Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expressionCancer Gene Therapy.  10:330-339. 2003
    2002 Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosisCancer Biology and Therapy.  1:401-406. 2002
    1999 Molecular analysis of the cryptococcus neoformans ADE2 gene, a selectable marker for transformation and gene disruptionExperimental mycology.  27:36-48. 1999
    1996 2-keto-3-deoxy-6-phosphogluconate aldolases as catalysts for stereocontrolled carbon-carbon bond formationJournal of the American Chemical Society.  118. 1996
    1996 2-Keto-3-deoxy-6-phosphogluconate aldolases as catalysts for stereocontrolled carbon-carbon bond formationJournal of the American Chemical Society.  118:2117-2125. 1996
    1973 Clinical trial with pyrantel pamoate (Combantrin) in ancylostomiasis.Journal of the Association of Physicians of India.  21:833-839. 1973

    Research Overview

  • The Metabolic Basic of Kidney Cancer - Our laboratory’s principal focus has been to study the metabolic alterations of kidney cancer, also referred to as renal cell carcinoma (RCC). We study both rare hereditary forms of RCC as well as in sporadic kidney cancer. We are interested in hereditary forms of renal cancer as we believe the study of these disease variants can provide insight into more common, sporadic forms of this disease. We are interested in how metabolic remodeling contributes to tumor formation, progression, as well as response to therapy. In particular, our laboratory is interested in the connection between tumor metabolism and epigenetics. The overarching goal is to perform mechanistic studies that will advance our current knowledge base of kidney cancer in order to develop better methods to treat patients with advanced disease.

    Keywords - urologic oncology, scientific research understanding the molecular basis of renal cancer
  • Investigator On

  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Cancer Cell Biology Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2017 - 2020
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • UAB 1360: Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-Muscle-Invasive Transitional Cell Bladder Cancer  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2014 - 2019
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION 2015 - 2019
  • Private Grant  awarded by VIVENTIA BIO, INC. 2017 - 2018
  • Registry for Treatment of Upper Urinary Tract Tumours: A Multi-Center, International Registry to Evaluate the Treatment of Upper Tract Urothelial Cancer (UTUC): Incidence, Indications, Treatment types and Outcomes  awarded by THE ENDOUROLOGY SOCIETY 2016 - 2017
  • A Phase II Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract (PFE/PomX) in Subjects with Clinically Localized Prostate Cancer Undergoing Active Surveillance  awarded by University of Wisconsin-Madison 2013 - 2016
  • A Specific Screening Strategy to Reduce Prostate Cancer Mortality  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2012 - 2015
  • Private Grant  awarded by LEIDOS BIOMEDICAL RESEARCH, INC. 2013 - 2014
  • Tissue Resource Site (TSS) in Support of the The Cancer Genome Atlas (TCGA) Program - Admin Core  awarded by SAIC - FREDERICK 2013 - 2014
  • Education And Training

  • Doctor of Medicine, Duke University 1999
  • Medical University of South Carolina Medical Cente, Residency 2005
  • Medical University of South Carolina Medical Cente, Residency 2002
  • National Cancer Institute, Postdoctoral Fellowship 2007
  • Full Name

  • Sunil Sudarshan